CA Patent

CA2805600C — Medicaments containing vardenafil hydrochloride trihydrate

Assigned to Bayer Intellectual Property GmbH · Expires 2018-12-18 · 7y expired

What this patent protects

The invention relates to a storage-stable rapid-release vardenafil hydrochloride tablet comprising vardenafil hydrochloride trihydrate and one or more suitable excipients, wherein the vardenafil hydrochloride trihydrate content in the tablet is at least 90 mol% and the tablet is …

USPTO Abstract

The invention relates to a storage-stable rapid-release vardenafil hydrochloride tablet comprising vardenafil hydrochloride trihydrate and one or more suitable excipients, wherein the vardenafil hydrochloride trihydrate content in the tablet is at least 90 mol% and the tablet is uncoated.

Drugs covered by this patent

Patent Metadata

Patent number
CA2805600C
Jurisdiction
CA
Classification
—
Expires
2018-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Bayer Intellectual Property GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.